Cyclooxygenases, particularly COX-2, play an important role in tumor development and progression. We have previously shown that COX-2 expression is an independent prognostic factor in human ovarian carcinoma. In this study, we investigated the effects of the inhibition of COX isoforms by the NSAID NS-398 as well as by COXisoform-specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1 and an induction of high levels of COX-2 and PGE 2 after stimulation with interleukin-1b. In contrast, SKOV-3 cells were negative for both COX isoforms. In OVCAR-3 cells, PGE 2 production was inhibited by NS-398 in concentrations of 1 lm and by a COX-2-specific silencing RNA (siRNA), while a COX-1-specific siRNA did not have an effect. This suggests that COX-2 is the major source of PGE 2 in this cell line. To dissociate COX-2-specific and non-COX-2-specific effects on cell proliferation, a proliferation assay was performed after incubation of cells with NS-398 and COX siRNAs. NS-398 induced an inhibition of cell proliferation at concentrations of 50-500 lm, which are above the concentrations needed for the inhibition of PGE 2 production. This inhibitory effect was present in the COX-positive cell line OVCAR-3 as well as in the COX-negative cell line SKOV-3 and could not be reverted by addition of exogenous PGE 2 . Neither COX-1-nor COX-2-specific siRNAs had an effect on cell proliferation of OVCAR-3 cells. Cell cycle analysis showed an increased accumulation of cells in the G0/G1 phase after treatment with NS-398, but not with COX siRNAs. These experiments suggest that NS-398 reduced cell proliferation in ovarian carcinoma cells by induction of G0/G1 cell cycle arrest independent of COX-2 inhibition. Our study shows that specific inhibition of COX isoforms by RNAi could be used to dissociate effects of NSAIDs. Furthermore, our results suggest that cell cycle arrest is one of the primary mechanisms responsible for the antiproliferative effects of NS-398 on ovarian carcinoma cells.
Introduction
Cyclooxygenases (COX) are the rate-limiting enzymes involved in the production of prostaglandins (PGs). Two isoforms of COX have been described: COX-1 is expressed constitutively in many tissues, while COX-2 is inducible by tumor promoters, inflammatory cytokines and growth factors (O'Banion et al., 1992) . Several lines of evidence suggest that COX, particularly COX-2, play an important role in tumor development and progression. COX-2 is upregulated in many malignant tumors and a high expression of COX-2 in tumor tissue is related to poor prognosis in several tumor types (Shono et al., 2001; Ristima¨ki et al., 2002) . COX are particularly interesting potential targets for tumor therapy since well-characterized inhibitory substances of COX, the nonsteroidal anti-inflammatory drugs (NSAIDs), are already available. These substances have been in clinical use as an anti-inflammatory medication for a long time. Epidemiological studies have shown that use of NSAIDs is also linked to a reduced cancer risk (Thun, 1994; Khuder and Mutgi, 2001) .
The role of COX-2 in malignant tumors has been investigated in many different experimental systems. These studies have revealed COX-2-related mechanisms involved in the progression of malignant tumors, such as inhibition of apoptosis (Tsujii and DuBois, 1995) , increased angiogenesis (Tsujii et al., 1998) , increased invasion (Tsujii et al., 1997) and modulation of inflammation (Huang et al., 1998) . In an animal model of familial adenomatosis coli, inhibition of COX-2 reduced the number and size of intestinal polyps, suggesting that COX-2 might be involved in carcinogenesis in this model (Oshima et al., 1996) . In addition to these results, however, there has been evidence suggesting that the antitumor effect of NSAIDs may not be mediated solely by COX-2, but that NSAIDs act on different cellular targets, as well. For example, NSAIDs inhibit the growth of both COX-2-negative and -positive cells (Yip-Schneider et al., 2000) . Derivates of NSAIDs without anti-COX activity are active against tumor cells in some experimental systems (Thompson et al., 1995) .
COX-inhibitors exert their effects on a wide variety of different tumors and have been studied in many different experimental models. Since they most likely act on different targets in these models, it would be important to use a comparably easy method for specific inhibition of different COX-isoforms. In this study, we show that RNA interference (RNAi) (Fire et al., 1998; Caplen et al., 2001; Elbashir et al., 2001) can be used for highly specific inhibition of COX-2. This method could be easily adapted to different experimental models and could be used as a tool to dissociate the effects of COX inhibitors.
We and others have recently shown that COX-2 is expressed in a subset of ovarian carcinomas and that a high expression of COX-2 is related to poor patient prognosis (Denkert et al., 2002; Ferrandina et al., 2002b) . Based on these results, the question arises whether COX-2 inhibitors would be a new therapeutic option for ovarian carcinoma. To investigate this hypothesis, we studied effects of the COX-2 inhibitor NS-398 as well as specific inhibitory siRNAs against COX-1 and COX-2 on the ovarian carcinoma cell lines OVCAR-3 and SKOV-3. As we have previously shown, COX-2 is highly inducible in OVCAR-3 cells by interleukin-1b (IL-1b), resulting in the production of high levels of PGE 2 . In contrast, SKOV-3 cells are negative for COX-2. We used OVCAR-3 and SKOV-3 as model cell lines to investigate the effects of inhibition of COX isoforms by siRNA as well as by the NSAID NS-398.
Results

RNAi is functional in OVCAR-3 cells
To investigate whether RNAi is functional in OVCAR-3 ovarian carcinoma cells, we studied the inhibition of lamin A/C by a specific siRNA. The nuclear protein lamin A/C has been suggested as a control protein for RNAi by Elbashir et al. (2001) and is widely used for evaluation of RNAi. As shown in Figure 1a and b, lamin A/C immunofluorescence was reduced in about 90% of cells after incubation with a lamin A/C siRNA (60 pmol/l) for 48 h. Using different concentrations of siRNA, we showed by immunoblotting that lamin A/C protein expression was inhibited after 48 h by siRNA concentrations between 1 and 60 pmol/l, with maximal inhibition already at a siRNA concentration of 10 pmol/ l (Figure 1c) . In time course experiments, inhibition of lamin A/C protein expression by interfering RNAs (60 pmol/l) was observed after 48 h and was present for up to 6 days ( Figure 1d ). These results show that RNAi is functional in OVCAR-3 cells and that the transfection efficiency is around 90%.
Expression and regulation of COX-1 and COX-2 in ovarian carcinoma cells
In a previous study, we have investigated the expression of COX-1 and COX-2 mRNA as well as protein levels in a panel of human ovarian carcinoma cell lines (Denkert et al., 2002) . We found that in OVCAR-3 cells, COX-2 mRNA as well as protein is highly inducible after treatment with interleukin-1b (IL-1b), resulting in the production of high levels of PGE 2 . Further investigations showed that COX-2 mRNA levels were increased for 1-24 h after treatment with 10 ng/ml IL-1b (Figure 2a) . On the protein level, there was a concentration-dependent induction of COX-2 by IL-1b (0.1-10 ng/ml) after 24 h (Figure 2b ). Based on these results, we selected OVCAR-3 cells as a model cell line to study the role of COX-2 in ovarian carcinoma. For some experiments, SKOV-3 was used as an additional cell line. SKOV-3 cells were negative for COX-2 and COX-1 protein even after stimulation with IL-1b and did not produce detectable levels of PGE 2 (Denkert et al., 2002) . As shown in Figure 2c , IL-1b-induced COX-2 protein expression of OVCAR-3 cells was inhibited strongly by a COX-2 siRNA at concentrations between 10 and 60 pmol/l, with detectable inhibition already at concentrations of 1 pmol/l. In contrast, the expression of COX-1, which is expressed constitutively by OVCAR-3 cells, was not inhibited by COX-2 siRNA ( Figure 2c ).
As shown in Figure 2d , there was a partial inhibition of COX-1 mRNA levels after 48 h by the COX-1 siRNA (60 pmol/l). These effects were present in the presence as well as in the absence of IL-1b stimulation. Similar effects were observed after 72 h. There was no inhibition of COX-2 protein expression by the siRNA against COX-1. In addition, we have constructed and tested another siRNA against COX-1, which showed a similar inhibitory capacity (data not shown).
Inhibition of PGE 2 production of OVCAR-3 cells by COX-2 siRNA Since OVCAR-3 cells express the isoforms COX-1 and COX-2, which are both capable of production of PGE 2 , specific inhibition of COX isoforms by siRNA could be used to investigate the contribution of either enzyme to IL-1b-induced PG production. As shown in Figure 3 , inhibition of COX-2 by siRNA (60 pmol/l) results in a significant reduction of IL-1b-induced PGE 2 production measured by specific ELISA. While control cells (treated with transfection reagent alone) produce 91687258 pg/ml PGE 2 upon stimulation with IL-1b for 24 h, PGE 2 levels were reduced to 34227423 pg/ml after inhibition of COX-2. In contrast, inhibition of COX-1 had no effect on PGE 2 production (90097153 pg/ml). In our experiments, PGE 2 production is not completely inhibited by the COX-2 siRNA. This may be explained by the transfection efficiency of approximately 90%, which will still leave 10% cells without inhibition of COX-2. These low levels of COX-2 protein may be below the detection limit of the Western blot, but may lead to an accumulation of PGE 2 in the supernatant that can be detected by the more sensitive ELISA technique. Although we cannot exclude the fact that COX-1 may contribute partially to the production of PGE 2 , our results suggests that COX-2 is the main source of PGE 2 in this cell line. Figure 2 Expression and inhibition of COX-2 and COX-1 in OVCAR-3 cells. Expression of COX-2 mRNA as measured by PCR is induced after treatment with IL-1b for 1-24 h (a). COX-2 protein level as measured by immunoblotting is increased by treatment with IL-1b (0.1-10 ng/ml) for 24 h (b). Treatment with a COX-2 siRNA for 48 h completely inhibited IL-1b-induced COX-2 expression at siRNA concentrations between 10 and 60 pmol/l, without any effect on COX-1 expression (c). After treatment of cells with a COX-1-specific siRNA (60 pmol/l), a moderate decrease of COX-1 protein level was observed after 48 h (d). Data shown are representative of two to three independent experiments Figure 3 Inhibition of IL-1b-induced PGE 2 production by COX siRNA. Treatment with a COX-2 siRNA (60 pmol/l) reduced the IL-1b-induced PGE 2 production of OVCAR-3 cells, as measured by specific ELISA. In contrast, a COX-1 siRNA did not have any effect on PGE 2 production. Mean and s.d. of three independent experiments are shown COX-2-specific RNA interference in ovarian carcinoma C Denkert et al
Evaluation of NS-398 effects on PGE 2 production and cell viability
To evaluate the effects of the NSAID NS-398 on ovarian carcinoma cells, we measured the inhibition of PGE 2 production after treatment with NS-398. In OVCAR-3 cells, IL-1b-induced PGE 2 production was inhibited completely by NS-398 already at inhibitor concentrations of 1 mm (Figure 4 ). These results support the conclusion that COX-2 is the main source of PGE 2 in OVCAR-3 cells, since PGE 2 is inhibited at inhibitor concentrations that are far below the IC 50 for inhibition of COX-1.
We further investigated the effect of NS-398 on cell proliferation using an XTT proliferation assay. In OVCAR-3, we found a suppression of cell proliferation after treatment for 72 h with NS-398 at concentrations of 50-500 mm (Figure 5a ). This suppression was detectable in the presence and in the absence of IL-1b, but it was increased upon additional stimulation with IL-1b. In contrast to the strong inhibitory effect on PGE 2 production, low concentrations of NS-398 (1 mm) did not have an effect on cell proliferation (Figure 5a ). Addition of exogenous PGE 2 (10 mm) did not inhibit the antiproliferative effect of NS-398 on OVCAR-3 cells (Figure 5b ). This suggests that the antiproliferative effect of NS-398 may not be mediated by inhibition of COX-2 and PGE 2 production.
To evaluate cytotoxic effects of NS-398, lactate dehydrogenase activity (LDH) was measured in the cell culture supernatant of OVCAR-3 cells after treatment with NS-398 (1-500 mm) for 48-72 h with or without addition of IL-1b. Under these conditions, no increase of LDH activity was observed in NS-398-treated cells compared to control cells (data not shown).
SKOV-3 cells, which are negative for COX-1 and COX-2 protein, showed a similar inhibition of cell proliferation upon addition of high levels of NS-398 ( Figure 5c ). Similar to OVCAR-3 cells, addition of exogenous PGE 2 did not change the inhibitory effects of NS-398 on SKOV-3 cells (data not shown). This suggests that the effects of NS-398 in cell proliferation Figure 4 Inhibition of IL-1b-induced PGE 2 production by different concentrations of NS-398. IL-1b-induced PGE 2 production of OVCAR-3 as measured by specific ELISA is inhibited completely by NS-398 in a concentration of 1 mm. Mean and s.d. of three independent experiments are shown Figure 5 Inhibition of cell proliferation of OVCAR-3 cells and SKOV-3 cells by NS-398. OVCAR-3 cells were treated with NS-398 (50-500 mm) in the presence (solid line) and absence (dotted line) of IL-1b for 72 h and cell proliferation was measured using an XTTtest (a). Addition of exogenous PGE 2 (solid line) did not change the inhibitory effect of NS-398 (dotted line) on proliferation of OVCAR-3 cells (b). In SKOV-3 cells, which are negative for COX-1 and COX-2 protein, a similar reduction of cell proliferation by NS-398 was observed in the presence (solid line) and absence (dotted line) of IL-1b (c). Treatment of OVCAR-3 cells with indomethacin (50-500 mm), which has a higher specificity for COX-1 than for COX-2, resulted in a similar inhibition of cell proliferation as NS-398 (d). Mean and s.e.m. of at least three independent experiments are shown COX-2-specific RNA interference in ovarian carcinoma C Denkert et al are not dependent on the presence of COX-2 activity and PGE 2 .
To evaluate the contribution of COX-1 further, we investigated cell proliferation of OVCAR-3 cells after treatment with indomethacin. Although indomethacin inhibits COX-1 and COX-2, it has a higher selectivity for COX-1 (IC 50 : 0.013 mm, whole blood assay) than for COX-2 (IC 50 : 1.0 mm, Warner et al., 1999) . As shown in Figure 5d , a 50% inhibition of cell proliferation was observed at indomethacin concentrations of approximately 200 mm, which is far above the reported IC 50 for COX-1 or COX-2.
NS-398, but not COX SIRNAS, affect cell proliferation
We used specific inhibition of COX-1 and COX-2 by RNAi to investigate the role of these COX isoforms in cell proliferation. OVCAR-3 cells were incubated with NS-398 (200 mm) or COX-1 or COX-2 siRNAs (60 pmol/l) for 72 h and cell proliferation was measured using an XTT assay. As shown in Figure 6a and b, in contrast to NS-398, neither inhibition of COX-2 nor inhibition of COX-1 had an effect on cell proliferation. In additional experiments, we investigated whether the inhibition of cell proliferation by NS-398 would be reduced after pretreatment with either COX-1 or COX-2 siRNA. This pretreatment did not change the cells' response to NS-398 (data not shown). These results indicate that the inhibitory effect of NS-398 on cell proliferation is not mediated by inhibition of COX.
NS-398 induces a G0/G1 cell cycle arrest
It has been shown that inhibitors of COX increase apoptotic cell death in tumor cell lines. To test this hypothesis in OVCAR-3 cells and SKOV-3 cells, we measured apoptosis by annexin V staining as well as DNA flow cytometry. With these methods, we did not observe a subG1-peak or an increased percentage of annexinV-positive cells after treatment with NS-398 (data not shown). Thus, there was no significant increase in apoptotic cells after treatment with NS-398. As shown in Figure 7 and Table 1 , treatment of cells with NS-398 induces an accumulation of OVCAR-3 and SKOV-3 cells in the G0/G1 phase of the cell cycle in the presence and absence of IL-1b. Under control conditions, 40.272.5% of OVCAR-3 cells are in the G0/G1 phase of the cell cycle, and after treatment with NS-398 (200 mm) for 24 h the percentage of cells in the G0/G1 phase is increased to 5376.7% (P ¼ 0.0002). In contrast, inhibition of COX-1 or COX-2 by RNAi had no influence on cell cycle distribution of OVCAR-3 cells (Table 2) or SKOV-3 cells (not shown).
Discussion
In this study, we have investigated the role of NSAIDs in ovarian carcinoma and we have shown that treatment with NS-398 resulted in reduced proliferation and growth arrest of tumor cells. Several lines of evidence suggest that this effect is not mediated by inhibition of COX-2, but by a non-COX-2-related effect. First, the concentration of NS-398 needed for inhibition of proliferation was much higher than for complete inhibition of PGE 2 production. Second, the antiproliferative effect was observed in a COX-2-negative cell line (SKOV-3) as well. Third, addition of exogenous PGE 2 did not change the inhibitory effect on cell proliferation. Based on these indirect hints that suggest an involvement of a non-COX-target in NSAID actions, we have used RNAi as a novel inhibitory strategy to dissociate effects related to inhibition of COX-1 and COX-2. While treatment with a siRNA against COX-2 resulted in the inhibition of COX protein levels as well as PGE 2 synthesis, this specific siRNA neither had influence on cell proliferation nor on cell cycle distribution.
To our knowledge, this is the first study that uses RNAi for determination of specificity of NSAIDs and this is the first description of NS-398-induced G0/G1 arrest in ovarian carcinoma cells. One other study has investigated the effects of NS-398 and other antiinflammatory drugs on ovarian carcinoma cell lines and found a reduction of cell proliferation in cells treated with NS-398, without investigating changes in These results are in line with our results. An effect of NS-398 on cell cycle distribution leading to accumulation of cells in the G0/G1 phase has been described for pancreatic tumor cell lines before (Yip-Schneider et al., 2001) . The mechanism by which NS-398 regulates the cell cycle distribution of ovarian carcinoma cells remains to be investigated. The cell cycle progression is regulated by a network of cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CDKIs). For other cell types, it has been shown that treatment of cells with NSAIDs results in upregulation of CDKIs that regulate accumulation of cells in G0/G1. In colon cancer cells, sulindac was found to increase the expression of p21WAF1 (Goldberg et al., 1996) . Similarly, NS-398 induced p21WAF1 protein (Toyoshima et al., 2002) in squamous cell carcinoma. In human lung cancer cells, p27KIP1 (Hung et al., 2000) is induced by NSAID treatment. Further studies are required to investigate whether a similar contribution of p21 or related proteins, such as p27KIP1 and p57KIP2, to NS-398-induced growth arrest can be observed in OVCAR-3 cells.
We and others found that treatment with NS-398 results in a dysregulation of cell cycle distribution. In contrast, other authors showed an induction of apoptosis by COX-inhibitors. For example, it has been shown for colon cancer cells that NS-398-induced apoptosis in COX-2-positive and -negative cell lines without affecting cell cycle distribution (Elder et al., 1997) . The effects of NSAIDs on different types of tumor cells are variable and depend on the cell type as well as on the type of inhibitor that is used.
In our experiments, the expression of COX-2 is almost completely downregulated by the specific siRNA without producing any effect on cell proliferation. Therefore, we believe that our results exclude a contribution of COX-2 to the effects of NS-398 on cell proliferation and cell cycle distribution. In contrast, COX-1 protein expression is only partially inhibited by the COX-1 siRNA. We have tested two different COX-1 siRNAs, and both of them only induced a partial . In our experiments, we show that the partial inhibition of COX-1 protein levels did not have any effect on PGE 2 levels, cell proliferation and cell cycle distribution. Based on these results, we believe that a relevant contribution of COX-1 to the effects of NS-398 is unlikely. However, at present we cannot exclude the fact that a more effective inhibition strategy of COX-1 may show additional effects on the cells. COX-2-dependent and COX-2-independent effects of COX inhibitors are not exclusive, and they may both have a role in the biological activity of NSAIDs. To determine possible indications for NSAIDs in tumor therapy, it is important to investigate and separate COX-dependent and COX-independent effects of NSAIDs and the corresponding cellular targets for each tumor type and experimental model. In situations where the antitumor effect of NSAIDs is mediated by inhibition of COX-2, it might increase the patients' response rate to therapy if the tumor tissue is tested for COX-2 overexpression prior to therapy and if treatment is administered selectively to patients with a high expression of COX-2 in tumor tissue. On the other hand, if NSAIDs act on different cellular targets, it would be interesting to test patient tumors for expression of this target and to use it as a parameter for indication and control of therapy. Taken together, our study shows that specific inhibition of COX by RNAi can be used to dissociate effects of NSAIDs. Furthermore, our results suggest that cell cycle arrest is one of the primary mechanisms responsible for the antiproliferative effects of NS-398 on ovarian carcinoma cells, and that this effect is not mediated by inhibition of COX-2.
Materials and methods
Cell lines
The human ovarian carcinoma cell lines OVCAR-3 (Hamilton et al., 1983) and SKOV-3 (Fogh, 1975) have been isolated from ovarian adenocarcinomas and were obtained from ATCC. Cells were cultured in DMEM (Bio Whittaker Europe, Verviers, B) supplemented with 10% fetal bovine serum (PAA Laboratories, Linz, Austria) at 371C in a humidified 5% CO 2 incubator.
Construction of silencing RNAs (siRNAs)
SiRNAs against COX-1 and COX-2 were constructed as described by Elbashir et al. (2002) and chemically synthesized (Xeragon, Huntsville, AL, USA). The target sequence for the COX-2 siRNA was bases 291-313 of NM000963.1 (5 0 aactgctcaacaccggaattttt3 0 ). The target sequence of the COX-1 siRNA was bases 1533-1555 of M59979.1 (5 0 aagtgccatccaaactctatctt3 0 ). For additional experiments a second COX-1 siRNA was used, which was directed against the target sequence 1719-1741 (5 0 aagacctgtccctacgtttcctt3 0 ) of M59979.1. All siRNAs were controlled for sequence specificity by a BLAST search and did not show homology to other known human genes. The lamin A/C siRNA sequence has been described before by Elbashir et al. (2001) ; this siRNA as well as an unspecific control (nonsilencing) siRNA (cat. No. 80-11310) against the target sequence 5 0 aattctccgaacgtgtcacgttt3 0 was synthesized by Xeragon.
Transfections
OVCAR-3 cells were plated at a density of 25 000 cells/well in 24-well plates and grown to 50% confluence. After 24 h, the cells were transfected with siRNA in oligofectamine reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Briefly, for each well, 3 ml oligofectamine reagent was incubated with 12 ml of serum-free medium for 7-10 min. Subsequently, a mixture of 3 ml of the respective siRNA in annealing buffer stock and 50 ml medium was added.
After incubation for 15-20 min at room temperature, 32 ml medium was added to the dilution, mixed again and 100 ml transfection mixture was added to each well, resulting in a siRNA concentration of 60 pmol/l.
Immunofluorescence of lamin A/C expression
Immunohistochemical staining was performed according to standard procedures. Briefly, subconfluent cells grown in 24-well plates were transfected with lamin A/C siRNA. After 48 h, cells were fixed in methanol for 10 min at À201C. Slides were incubated with lamin A/C-specific antibody diluted 1 : 100 in PBS/1%BSA for 90 min at 211C, followed by incubation with a cy3-conjugated anti-mouse antibody (Dianova, Hamburg, Germany) diluted 1 : 200 in PBS/1%BSA. In addition, cell nuclei were stained with DAPI (1 : 1000). Confocal laser scanning microscopy was performed using a Leica confocal microscope.
Immunoblotting OVCAR-3 cells were plated at a density of 25 000 cells/well in 24-well plates, grown to 50% confluence and were transfected with siRNAs. As indicated, cells were stimulated 24 h after transfection with 10 ng/ml recombinant human IL-1b (R&D systems, Minneapolis, MN, USA) for 24 h. Cells were harvested in 100 ml of 62.5 mm Tris-HCl (pH6.8) containing 2% sodium dodecyl sulfate, 10% glycerol and 50 mm DTT. In all, 100 mg protein/sample was loaded on a 10% polyacrylamide gel. Proteins were blotted onto nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany), washed in PBS and incubated in blocking buffer (1 Â PBS, 0.1% Tween-20, 5% Iblock (Tropix, Bedford, MA, USA)) for 1 h at 181C. Membranes were incubated overnight at 181C with a monoclonal anti-COX-1 antibody (1 : 1000, Cayman Chemical, Ann Arbor, MI, USA), monoclonal anti-COX-2 antibody (1 : 1000, Cayman Chemical) or monoclonal mouse anti-human lamin A/C antibody (1 : 50, Chemicon, Temcula, CA, USA) in blocking buffer, followed by incubation with alkaline phosphatase-conjugated goat-anti-mouse secondary antibody (Tropix, Bedford, MA, USA). Bands were visualized using the CDP star RTU luminescence system (Tropix).
Polymerase chain reaction
COX-2 mRNA levels were determined by PCR as described (Denkert et al., 2002) . Briefly, cells were stimulated with IL-1b (10 ng/ml) for times as indicated. Total RNA was prepared 
Proliferation assay
OVCAR-3 cells were plated in quadruplets for each concentration in 96-well plates (3000 cells/well) and incubated with different concentrations of NS-398 for 72 h in a serum-free cell culture medium. NS-398 (Alexis, Gru¨nberg, Germany) was dissolved in DMSO (Sigma, Deisenhofen, Germany). Cells were stimulated with IL-1b (10 ng/ml) (R&D Systems) 1 h after NS-398-addition. Cell number was determined using a tetrazolium conversion assay (Boehringer, Mannheim, Germany) according to the manufacturer's instructions. For some experiments, cells were incubated with indomethacin (50-500 mm, Sigma, Deisenhofen, Germany).
In some experiments, cells that had been transfected with siRNA in 24-well pates were stimulated with IL-1b after 24 h and analysed by the tetrazolium conversion assay.
LDH assay
To evaluate cytotoxic effects of NS-398, LDH was measured. OVCAR-3 cells were incubated with NS-398 (1-500 mm) for 48-72 h with or without the addition of IL-1b. Cell culture supernatants were collected and LDH activity was measured in the cell culture supernatant using the cytotoxicity detection kit (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions.
Apoptosis assays
Cells were evaluated for evidence of apoptosis by measurement of the DNA content by propidium iodide (PI) staining as previously described by Nicoletti et al. (1991) . Briefly, cells were seeded at a density of 5 Â 10 5 cells/well in six-well plates and were treated with NS-398 (200 mm) after 24 h. After 48 h, cells and supernatants were collected together, centrifuged at 1000 rpm for 5 min and pelleted. The pellet was vortexed and incubated with 200 ml Nicoletti reagent (PI 50 mg/ml; 0.1% sodiumcitrate; 0.1% triton) overnight at 41C in the dark. Core DNA content was measured using a logarithmic amplification in the FL-3 channel of a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany) using CellQuest software (Version 4.0.2., Becton Dickinson).
In an additional set of experiments, apoptosis was measured by annexin V binding (Becton Dickinson) according to the manufacturer's protocol. Cells were immediately measured with the FACScan Flow cytometer and analysed with CellQuest software.
Cell cycle analysis
For analysis of cell cycle distribution, the DNA content of individual cells was measured by flow cytometry. Cells were seeded at a density of 5 Â 10 5 cells/well in six-well plates. After 24 h, cells were stimulated either with NS-398 or transfected with siRNAs, respectively. After 24 h, cells and supernatants were collected together, and were treated with Nicoletti reagent. Core DNA content was measured using a linear amplification in the FL-2 channel of a FACScan flow cytometer using the CellQuest software. Cell cycle was analysed by ModFit LT software (Version 3.0, Verity Software, Topsham, USA). For statistical analysis, the Student's t-test was used. P-values o0.05 were considered significant.
PGE 2 ELISA
A total of 2 Â 10 5 cells/well were seeded in 24-well plates in DMEM 10% FCS. After 24 h, cells were incubated with NS-398 (1-500 mm) for 1 h or transfected with siRNAs (60 pmol/l) for 24 h and were subsequently stimulated with IL-1b (10 ng/ml) for another 24 h. Supernatants were harvested, centrifuged at 5000 rpm for 10 min and stored at À801C. Concentrations of PGE 2 in cell culture supernatants were determined using a specific ELISA (R&D Systems) according to the manufacturer's instructions. The concentration of PGE 2 was estimated from the absorbance of the calculated standard curve. Abbreviations COX, cyclooxygenase; PG, prostaglandin; NSAID, nonsteroidal anti-inflammatory drug; XTT, 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt.
